↓ Skip to main content

PLOS

Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery

Overview of attention for article published in PLOS ONE, November 2012
Altmetric Badge

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
45 X users
facebook
2 Facebook pages
googleplus
1 Google+ user
reddit
1 Redditor
f1000
1 research highlight platform

Citations

dimensions_citation
60 Dimensions

Readers on

mendeley
211 Mendeley
citeulike
4 CiteULike
Title
Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery
Published in
PLOS ONE, November 2012
DOI 10.1371/journal.pone.0048476
Pubmed ID
Authors

Peter S. Kutchukian, Nadya Y. Vasilyeva, Jordan Xu, Mika K. Lindvall, Michael P. Dillon, Meir Glick, John D. Coley, Natasja Brooijmans

Abstract

Medicinal chemists' "intuition" is critical for success in modern drug discovery. Early in the discovery process, chemists select a subset of compounds for further research, often from many viable candidates. These decisions determine the success of a discovery campaign, and ultimately what kind of drugs are developed and marketed to the public. Surprisingly little is known about the cognitive aspects of chemists' decision-making when they prioritize compounds. We investigate 1) how and to what extent chemists simplify the problem of identifying promising compounds, 2) whether chemists agree with each other about the criteria used for such decisions, and 3) how accurately chemists report the criteria they use for these decisions. Chemists were surveyed and asked to select chemical fragments that they would be willing to develop into a lead compound from a set of ~4,000 available fragments. Based on each chemist's selections, computational classifiers were built to model each chemist's selection strategy. Results suggest that chemists greatly simplified the problem, typically using only 1-2 of many possible parameters when making their selections. Although chemists tended to use the same parameters to select compounds, differing value preferences for these parameters led to an overall lack of consensus in compound selections. Moreover, what little agreement there was among the chemists was largely in what fragments were undesirable. Furthermore, chemists were often unaware of the parameters (such as compound size) which were statistically significant in their selections, and overestimated the number of parameters they employed. A critical evaluation of the problem space faced by medicinal chemists and cognitive models of categorization were especially useful in understanding the low consensus between chemists.

X Demographics

X Demographics

The data shown below were collected from the profiles of 45 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 211 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
United States 2 <1%
Netherlands 1 <1%
Bulgaria 1 <1%
Brazil 1 <1%
Portugal 1 <1%
Argentina 1 <1%
Germany 1 <1%
Spain 1 <1%
Other 1 <1%
Unknown 199 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 83 39%
Student > Ph. D. Student 40 19%
Student > Master 19 9%
Student > Doctoral Student 9 4%
Other 9 4%
Other 25 12%
Unknown 26 12%
Readers by discipline Count As %
Chemistry 104 49%
Agricultural and Biological Sciences 20 9%
Computer Science 11 5%
Biochemistry, Genetics and Molecular Biology 8 4%
Pharmacology, Toxicology and Pharmaceutical Science 7 3%
Other 27 13%
Unknown 34 16%